Tacrolimus in the treatment of severe chronic idiopathic urticaria: An open-label prospective study - 21/08/11
, Ellen Bamberger, MD, Elias Toubi, MD
Reprint requests: Aharon Kessel, MD, Division of Clinical Immunology and Allergy, Bnai Zion Medical Center, 47 Golomb St, P.O. Box 4940, Haifa 31048, Israel.Haifa, Israel
Abstract |
We report the result of a pilot study of low-dose tacrolimus for the treatment of patients with severe chronic idiopathic urticaria (CIU). Nineteen patients with severe CIU were treated with tacrolimus for 12 weeks. Two patients dropped out after 1 week of treatment because of side effects. Following 3 months of treatment, 12 of 17 patients (70.5%) had a clinical response to tacrolimus. In 9 patients, the urticaria had been improved significantly (urticarial score 0-1), enabling them to discontinue antihistamines and, in the case of two patients, corticosteroids. The remaining 3 patients had moderate improvement (urticarial score 2). Three months after the discontinuation of tacrolimus, 3 of 10 responders had a complete resolution of their urticaria (urticarial score 0), 3 had mild deterioration (urticarial score 1-2) controllable by antihistamines alone, and 4 patients had a full relapse (urticarial score 3). Our preliminary results suggest tacrolimus as a treatment option for patients with severe CIU.
Le texte complet de cet article est disponible en PDF.Plan
| Funding provided in part by Fujisawa, Inc. Conflicts of interest: None identified. |
Vol 52 - N° 1
P. 145-148 - janvier 2005 Retour au numéro
Article précédent
- Brachioradial pruritus is associated with a reduction in cutaneous innervation that normalizes during the symptom-free remissions
- Joanna Wallengren, Frank Sundler
- Lethal basal cell carcinoma secondary to cerebral invasion
- Carrie L. Kovarik, David Stewart, Jeffrey J. Barnard
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?